Loading organizations...
§ Private Profile · Ohio, IL, USA
Clinical-stage biopharma developing minimally invasive injectable regenerative therapeutics for osteoarthritis, meniscus tears, disc disease.
Based in Mason, Ohio, Amplicore is a clinical-stage biopharmaceutical company that develops injectable regenerative therapeutics for musculoskeletal diseases such as osteoarthritis, degenerative disc disease, and acute meniscus tears. The company's proprietary formulations are designed to relieve pain, restore joint function, and promote tissue regeneration without the need for invasive orthopedic surgeries. Operating with a team of fewer than 15 employees, the pre-revenue biotech startup recently initiated Phase 1/2b clinical trials for its lead candidate, AM3101, targeting acute meniscal tears. The enterprise has secured a $4 million seed funding round led by the Photon Fund, alongside investments from the JobsOhio Growth Capital Fund and Queen City Angels. Additionally, the organization has received over $5 million in non-dilutive grant funding from the National Institutes of Health and the Department of Defense. Amplicore was founded in 2019 by Dr. Chia-Ying James Lin.
Amplicore has raised $4.0M across 1 funding round.
Amplicore has raised $4.0M in total across 1 funding round.
Amplicore has raised $4.0M in total across 1 funding round.
Amplicore's investors include Photon Fund, Berkeley Catalyst Fund, ITIC, SVE Capital.
Amplicore has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 25, 2021 | $4M Seed | Photon Fund | Berkeley Catalyst Fund, Itic, SVE Capital | Announced |